Welcome to our dedicated page for Kazia Therapeutics American Depositary Shares news (Ticker: KZIA), a resource for investors and traders seeking the latest updates and insights on Kazia Therapeutics American Depositary Shares stock.
Kazia Therapeutics Limited (NASDAQ: KZIA) is an innovative biotechnology company focused on oncology, based in Sydney, Australia. The company is dedicated to developing cutting-edge anti-cancer drugs, with a robust pipeline aimed at addressing various forms of cancer.
The lead program for Kazia is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway. Paxalisib is primarily developed for treating glioblastoma multiforme, a highly aggressive brain cancer. Licensed from Genentech in late 2016, paxalisib has been the subject of numerous clinical trials. A Phase II study reported promising clinical activity, and the drug is currently undergoing pivotal trials, with additional studies targeting brain metastases and other central nervous system (CNS) cancers.
Besides paxalisib, Kazia is advancing EVT801, a small-molecule VEGFR3 inhibitor, licensed from Evotec SE in April 2021. EVT801 has shown preclinical efficacy across a range of tumor types and synergy with immuno-oncology agents. It's currently in Phase I clinical trials for advanced solid tumors.
Another notable drug in Kazia’s pipeline is Cantrixil (TRXE-002-1), under development for ovarian cancer and in Phase I clinical trials in Australia and the United States.
Kazia’s commitment to innovation and collaboration is evident through strategic partnerships and licensing agreements. For example, they recently signed a non-binding Letter of Intent with a biotechnology company to develop and commercialize paxalisib outside oncology, targeting epilepsy related to focal cortical dysplasia type 2 and tuberous sclerosis complex.
Financially, Kazia remains focused on securing funding to sustain its research and development endeavors. The company recently announced a direct offering expected to generate approximately $2 million.
Additionally, Kazia's forward-looking strategy includes addressing market listing requirements and ensuring compliance with Nasdaq’s Minimum Bid Price Requirement.
For more information, visit www.kaziatherapeutics.com or follow them on Twitter @KaziaTx.
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) announced on April 14, 2023, that it has regained compliance with Nasdaq's minimum bid price requirement. This follows a notification received on December 9, 2022, indicating non-compliance due to the company's American Depository Shares (ADSs) closing below US$ 1.00 for 30 consecutive business days. To maintain compliance, the company needed its ADS bid price to stay at or above US$ 1.00 for ten consecutive business days, which was achieved from March 29 to April 12, 2023. Kazia is focused on developing oncology treatments, specifically its lead program, paxalisib, aimed at various brain cancers, with clinical studies ongoing and promising interim data reported.
Kazia Therapeutics Limited (NASDAQ: KZIA) announced significant data on its drug candidates paxalisib and EVT801 at the AACR Annual Meeting in Orlando from April 14-19, 2023. Five presentations will highlight new findings, particularly for paxalisib's effectiveness in melanoma and childhood brain cancer, indicating enhanced overall survival in preclinical models. Additionally, EVT801's novel biomarker strategy is expected to yield initial clinical data in 2023. The presentations reinforce Kazia's ongoing collaboration with Evotec and suggest promising therapeutic paths for both compounds, particularly in combination therapies.
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) announced a placement of shares to institutional investors, aiming to raise
Kazia Therapeutics has entered a research collaboration with QIMR Berghofer Medical Research Institute to explore the use of its lead asset, paxalisib, in solid tumors. This initiative builds upon previously conducted preclinical studies, particularly in melanoma, and aims to evaluate paxalisib as a potential immune modulator in combination with existing checkpoint inhibitors like Keytruda and Opdivo. The results are anticipated in H1 CY23, with the possibility of clinical progression depending on the encouraging preclinical data.
FAQ
What is the current stock price of Kazia Therapeutics American Depositary Shares (KZIA)?
What is the market cap of Kazia Therapeutics American Depositary Shares (KZIA)?
What is Kazia Therapeutics’ primary focus?
What is paxalisib?
What stage are paxalisib’s clinical trials in?
What other drugs are in Kazia’s pipeline?
How is Kazia financing its projects?
What recent partnerships has Kazia formed?
What are the latest clinical trial developments for EVT801?
How does Kazia ensure compliance with Nasdaq’s listing requirements?
What is the significance of Kazia’s licensing agreement with Sovargen Co., Ltd?
Where can I find more information about Kazia Therapeutics?
